cognitive disorder

GR 125743 is a novel antagonist of 5-HT1B/1D receptor.

Guanfacine hydrochloride (Intuniv) is a centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

MK-0249 FA is an orally active, selective and potent histamine H3 inverse agonist for the study of attention deficit, hyperactivity disorder neurodivergent and cognitive disorders in adults.

AMPA receptor modulator-9 is a selective, orally active positive allosteric modulator of AMPARs, capable of crossing the blood-brain barrier. It selectively enhances AMPAR activity in human and rat models, with an EC2x value of 0.96 μM in rat embryonic cortical primary neurons. The compound upregulates BDNF protein expression in primary rat cortical neuron cultures and enhances AMPA-mediated excitatory postsynaptic responses in rats and mice. AMPA receptor modulator-9 is applicable for cognitive disorder studies.

PZ-1657 hydrochloride (Compound 57) is a potent, selective, and orally active 5-HT7 receptor inverse agonist, with a Ki value of 5 nM. It inhibits constitutive cAMP production mediated by the Gs signaling pathway, with an EC50 value of 2.93 nM. PZ-1657 hydrochloride significantly reduces 5-HT7 receptor-mediated MMP-9 activity in the mouse hippocampus, showing effects comparable to SB-269970. It reverses cognitive deficits induced by phencyclidine in a rat novel object recognition test without affecting spontaneous activity. PZ-1657 hydrochloride is useful for researching affective disorders such as depression and bipolar disorder.

SUVN-G3031 is a antagonist of histamine H3 receptor with potential for the treatment of cognitive impairment, dementia, attention deficit hyperactivity disorder, epilepsy, sleep disorders, obesity, schizophrenia, eating disorders, and pain.

Guanfacine-13C,15N3 is intended for us as an internal standard for the quantification of guanfacine by GC- or LC-MS. Guanfacine (T22824) is an α2-adrenergic receptor (α2-AR) agonist with Kivalues of 93, 1,380, and 3,890 nM for α2A-, α2B-, and α2C-ARs, respectively, in a radioligand binding assay.1It has EC50values of 52, 288, and 602 nM for α2A-, α2B-, and α2C-ARs, respectively, for stimulated [35S]GTPγS binding. It also binds to imidazoline receptor 1 (Ki= 19 nM in a radioligand binding assay).2Guanfacine (0.3-5 mg/kg) binds to adrenergic receptors in the central nervous system and lowers blood pressure in hypertensive rats in a dose-dependent manner.3It also improves spatial working memory deficits induced by hypobaric hypoxia in rats.4Formulations containing guanfacine are used in the treatment of high blood pressure and attention deficit hyperactivity disorder (ADHD).

Sofinicline benzenesulfonate (ABT 894 benzenesulfonate), a novel agonist of the nicotinic acetylcholine receptor, specifically targets the α4β2 subtype of nAChR (IC 50 =0.1 nM). This compound shows promise in enhancing cognitive functions such as attention, memory, and working memory. It is potentially useful in research pertaining to attention deficit hyperactivity disorder (ADHD).